Congress Center Basel

EQS-News: Ilmac 2023 in Basel was a resounding success

Retrieved on: 
Friday, September 29, 2023
Life, Marketing, Network, Chemical Society, Congress Center Basel, SKAN, TEL, Metrohm, SVC, Laboratory, Head Office, MCH Group, Institute of Chemical Technology, Mettler Toledo, Knowledge, GDK, Social, Conference, Georgia Department of Economic Development, Skan, Exhibition, Integra, MCH, University, O'Neill School of Public and Environmental Affairs, Agilent Technologies, Tourism, Future

Basel, 29 September 2023 – After three eventful days, Ilmac 2023 closed its doors allowing the organisers to look back on a successful event.

Key Points: 
  • Basel, 29 September 2023 – After three eventful days, Ilmac 2023 closed its doors allowing the organisers to look back on a successful event.
  • We will maintain this strategy in future to ensure a strong and successful Ilmac,’ says Céline Futterknecht (Brand Director, Ilmac).
  • The new Ilmac 365 platform enables both exhibitors and participants to prepare optimally for their Ilmac visit.
  • With Messe Basel, the Congress Center Basel, and Messe Zürich, MCH also operates Switzerland’s largest multifunctional event infrastructures in terms of surface area.

Microchip Unveils Industry’s First Terabit-Scale Secure Ethernet PHY Family with Port Aggregation for Enterprise and Cloud Interconnect

Retrieved on: 
Monday, September 19, 2022
NOS, Group, Open Compute Project, Optics, SAI, PHY, PLL, PAM4, Optical Internetworking Forum, Risk, Long Reach, IEEE 802.1AE, LLC, Software development kit, ECOC, Physics, Growth, OIF, Microchip Technology, Industry, Calendar, IEEE, MCHP, Library, Congress Center Basel, Dell Networking Operating System, Technology, Â, Integrated circuit, Solution, Silicon, Family, API, Ecosystem, European Conference on Information Systems, NASDAQ, OCP, IPsec, Conference, GLOBE, SDK, PTP, Internet service provider, Video game console, Mobile phone, U.S.A

This dramatic growth is expanding the transition to 112G PAM4 connectivity beyond just cloud data center and telecom service provider switches and routers to enterprise Ethernet switching platforms.

Key Points: 
  • This dramatic growth is expanding the transition to 112G PAM4 connectivity beyond just cloud data center and telecom service provider switches and routers to enterprise Ethernet switching platforms.
  • Microchip Technology Inc. (NASDAQ: MCHP) is responding to this market inflection with the META-DX2 Ethernet PHY (physical layer) portfolio by introducing a new family of META-DX2+ PHYs.
  • Microchips second-generation Ethernet PHY SDK for the META-DX2 family lowers development costs with field-proven API libraries and firmware.
  • Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries.

Boston Limited is partnering with Supermicro, Habana, an Intel company and SoftIron to showcase state-of-the-art AI technology, Intelligently Applied

Retrieved on: 
Wednesday, September 7, 2022
Cloud, Congress Center Basel, Machine learning, Booth, Patient, Technology, Intel, Liver, ST, HPC, Time, Intelligence, Solution, Health, Storage, Anomaly, Education, Deep learning, C20, Netlist (company), Medicine, Software design, Channel, Efficiency, Business, Marketing, Security, Automation, Social mobility, Industry, AI, Medical device, Video game console, Supermicro

ST ALBANS, England, Sept. 7, 2022 /PRNewswire/ -- Boston Limited, with thirty years of experience in providing high-performance technology, has partnered with Supermicro, Intel, and SoftIron at this year's Intelligent Health exhibition, booth C20, held on the 7th and 8th of September, as part of the world's leading AI in medicine summit series.

Key Points: 
  • The current and potential impact of artificial intelligence cannot be overstated, and Boston take a wide range of technologies and ensure they are Intelligently Applied to each customers requirements.
  • Boston is facilitating a data-centric future by incorporating automation, optimisation, and intelligence to further human innovation.
  • As well as consultancy, skills development, AI and enabling heterogenous computing, Boston has developed an algorithm to detect anomalies in dense organs, currently focussed on the liver.
  • Besides Supermicro, Boston is also bringing Habana, an Intel company, with its Gaudi 2 system to Intelligent Health 2022.

AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

Retrieved on: 
Monday, November 8, 2021
Congress Center, Industry, Private Securities Litigation Reform Act, CEO, COVID-19, Immunotherapy, Multimedia, Forward-looking statement, Congress, Cancer, Neoplasm, Congress Center Basel, Communication, Festival, Melanoma, Glioblastoma, Gemstone

IRVINE, Calif., Nov. 8, 2021 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will chair a keynote panel and speak on consecutive days at the World Immunotherapy Congress Europe.

Key Points: 
  • IRVINE, Calif., Nov. 8, 2021 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will chair a keynote panel and speak on consecutive days at the World Immunotherapy Congress Europe.
  • The congress is part of the Festival of Biologics taking place in Basel, Switzerland, November 9-11.
  • Dr. Keirstead's speaking details are as follows:
    Keynote panel discussion: What does the future of immunotherapy hold for oncology and infections diseases?
  • Panelists: Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, Roche Innovation Center Zurich; Jessica Flechtner, Chief Scientific Officer, Genocea Biosciences, Hans Keirstead, Chairman and CEO AIVITA Biomedical.

Addex to Present at the Swiss Biotech Day

Retrieved on: 
Thursday, September 2, 2021
Congress Center Basel, Lists of diseases, Epilepsy, Glutamate (neurotransmitter), Nasdaq, GABAB, Dyskinesia, Protein, ADX71149, Biotechnology, American depositary receipt, L-DOPA, Drug discovery, Glutamic acid, Therapy, Clinical trial, Glutamate receptor, Blepharospasm, Neurodegeneration, PAM, SIX Swiss Exchange, CEO, NAM, Allosteric regulation, Janssen Pharmaceuticals, PTSD, Pharmaceutical industry

Geneva, Switzerland, September 2, 2021 Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day , held September 7, 2021 at the Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland.

Key Points: 
  • Geneva, Switzerland, September 2, 2021 Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day , held September 7, 2021 at the Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland.
  • If you would like to schedule a meeting with Mr. Dyer, please send a request to: [email protected] .
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.